178 related articles for article (PubMed ID: 35288652)
1. Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia.
Amante E; Cerrato A; Alladio E; Capriotti AL; Cavaliere C; Marini F; Montone CM; Piovesana S; Laganà A; Vincenti M
Sci Rep; 2022 Mar; 12(1):4361. PubMed ID: 35288652
[TBL] [Abstract][Full Text] [Related]
2. Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine.
Cerrato A; Bedia C; Capriotti AL; Cavaliere C; Gentile V; Maggi M; Montone CM; Piovesana S; Sciarra A; Tauler R; Laganà A
Anal Chim Acta; 2021 May; 1158():338381. PubMed ID: 33863412
[TBL] [Abstract][Full Text] [Related]
3. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
4. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
[TBL] [Abstract][Full Text] [Related]
5. Untargeted Metabolomic Profile for the Detection of Prostate Carcinoma-Preliminary Results from PARAFAC2 and PLS-DA Models.
Amante E; Salomone A; Alladio E; Vincenti M; Porpiglia F; Bro R
Molecules; 2019 Aug; 24(17):. PubMed ID: 31443574
[TBL] [Abstract][Full Text] [Related]
6. Impact of prostate-specific antigen density in benign prostatic hyperplasia and prostate carcinoma. Preliminary results.
Akdaş A; Dillioğlugil O; Cevik I; Ilker Y
Eur Urol; 1994; 25(4):299-303; discussion 304. PubMed ID: 7519992
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
Front Oncol; 2021; 11():730638. PubMed ID: 34722271
[TBL] [Abstract][Full Text] [Related]
8.
Zniber M; Lamminen T; Taimen P; Boström PJ; Huynh TP
Heliyon; 2024 Apr; 10(7):e28949. PubMed ID: 38617934
[TBL] [Abstract][Full Text] [Related]
9. NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Kumar D; Gupta A; Mandhani A; Sankhwar SN
Prostate; 2016 Sep; 76(12):1106-19. PubMed ID: 27197810
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
Rezatabar S; Moudi E; Sadeghi F; Khafri S; Kopi TA; Parsian H
J Gene Med; 2020 Oct; 22(10):e3239. PubMed ID: 32529802
[TBL] [Abstract][Full Text] [Related]
11. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics.
Fernández-Peralbo MA; Gómez-Gómez E; Calderón-Santiago M; Carrasco-Valiente J; Ruiz-García J; Requena-Tapia MJ; Luque de Castro MD; Priego-Capote F
Sci Rep; 2016 Dec; 6():38243. PubMed ID: 27910903
[TBL] [Abstract][Full Text] [Related]
13. Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.
Ren S; Shao Y; Zhao X; Hong CS; Wang F; Lu X; Li J; Ye G; Yan M; Zhuang Z; Xu C; Xu G; Sun Y
Mol Cell Proteomics; 2016 Jan; 15(1):154-63. PubMed ID: 26545398
[TBL] [Abstract][Full Text] [Related]
14. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.
Pérez-Rambla C; Puchades-Carrasco L; García-Flores M; Rubio-Briones J; López-Guerrero JA; Pineda-Lucena A
Metabolomics; 2017; 13(5):52. PubMed ID: 28804274
[TBL] [Abstract][Full Text] [Related]
16. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
17. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
18. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
19. miRNA-21 as High Potential Prostate Cancer Biomarker in Prostate Cancer Patients in Indonesia.
Gunawan RR; Astuti I; Danarto HR
Asian Pac J Cancer Prev; 2023 Mar; 24(3):1095-1099. PubMed ID: 36974566
[TBL] [Abstract][Full Text] [Related]
20. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
Front Immunol; 2022; 13():998447. PubMed ID: 36685547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]